Prolonged administration over six hours of large doses of intravenous iron saccharate (500 mg) prevents severe adverse reactions in peritoneal dialysis patients.
Aggarwal
H K
HK
Tziviskou
E
E
Bellizzi
V
V
Khandelwal
M
M
Moupas
L
L
Bargman
J M
JM
Jassal
S V
SV
Oreopoulos
D G
DG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000209:etiology* / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D014677:Pharmaceutical Vehicles / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D014677:Pharmaceutical Vehicles; D007501:Iron